Goldman Sachs: The joint clinical research of Corun Bohai Biology (06990.HK) and sac-TMT therapy has reached the main endpoint, and we maintain a "buy" rating.

According to the Wise Finance APP, Goldman Sachs released a research report stating that they have raised Corning Biotec (06990.HK)'s earnings per share forecast for 2027 and 2028 to 7.51 RMB and 14.46 RMB respectively. The target price has been raised from 561.4 HKD to 582.95 HKD, maintaining a "buy" rating. Goldman Sachs believes that Corning Biotec has the potential to become a globally influential ADC pharmaceutical company.